Loading…
ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. (ADRX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in San Diego, United States and has 100 employees. The company is worth $1.89B. Revenue was $3.45M in fiscal 2025. It reported a net loss of $73.09M. The share price is 24.0% below its 52-week high of $23.21. None of the 38 superinvestors we track reported it in their latest 13F. Over the last 30 days, company insiders bought $17.13M of its stock on the open market and sold none.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in ADRX.
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ASTHAstrana Health, Inc. | $38.01 | 44.7x | 2.3x | 0.00% | 6.90% | $1.89B |
| ESTAEstablishment Labs Holdings Inc | $63.52 | — | 87.6x | 0.00% | -175.30% | $1.89B |
| XRAYDENTSPLY SIRONA Inc. | $9.50 | — | 1.4x | 1.68% | -33.03% | $1.89B |
| MLYSMineralys Therapeutics, Inc. |
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
1 methods answered, across 1 families.
Room for errors in the reported numbers.
+139.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| $21.47 |
| — |
| 3.4x |
| 0.00% |
| -80.88% |
| $1.9B |
| RXRXRecursion Pharmaceuticals Inc | $3.58 | — | 2.1x | 0.00% | -56.58% | $1.92B |
| SRPTSarepta Therapeutics, Inc. | $18.18 | — | 1.3x | 0.00% | -9.48% | $1.92B |